X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
USA (Orange Book)
Europe
0
Canada
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
Annual Reports
0
0
https://www.prnewswire.com/news-releases/xcopri-cenobamate-tablets-cv-receives-fda-approval-for-alternate-methods-of-administration-that-include-crushed-tablet-in-liquid-suspension-taken-orally-or-through-a-nasogastric-tube-302113538.html
https://www.prnewswire.com/news-releases/sk-life-science-announces-data-presentations-for-xcopri-cenobamate-tablets-cv-at-the-2024-american-academy-of-neurology-annual-meeting-302110843.html
https://www.fiercepharma.com/marketing/sk-life-science-marks-purple-day-epilepsy-awareness-highlighting-patient-support-programs
https://www.prnewswire.com/news-releases/endo-announces-approval-of-xcopri-cenobamate-tablets-in-canada-301866559.html#:~:text=DUBLIN%20and%20MONTREAL%2C%20June%2029,adults%20with%20epilepsy%20who%20are
https://www.prnewswire.com/news-releases/endo-announces-approval-of-xcopri-cenobamate-tablets-in-canada-301866559.html
https://www.pharmatimes.com/news/approval_provided_for_angelinis_cenobamate_1491639
https://www.prnewswire.com/news-releases/latest-xcopri-cenobamate-tablets-cv-post-hoc-analysis-presented-at-the-75th-american-academy-of-neurology-annual-meeting-301798363.html
https://www.prnewswire.com/news-releases/sk-life-science-presents-latest-data-on-xcopri-cenobamate-tablets-cv-in-adults-with-partial-onset-focal-seizures-at-the-aes-2022-annual-meeting-301690317.html
https://www.prnewswire.com/news-releases/sk-life-science-to-present-latest-xcopri-cenobamate-tablets-cv-data-at-the-american-epilepsy-society-2022-annual-meeting-301685636.html
https://www.pharmaceutical-technology.com/news/health-canada-paladin-seizure/
https://www.prnewswire.com/news-releases/new-drug-filing-for-cenobamate-accepted-for-review-in-canada-and-israel-301601069.html
https://www.prnewswire.com/news-releases/sk-biopharmaceuticals-eurofarma-enter-into-licensing-agreement-for-cenobamate-in-latin-america-301586292.html
https://www.prnewswire.com/news-releases/sk-life-science-presents-long-term-data-on-cognitive-and-psychiatric-adverse-events-associated-with-xcopri-cenobamate-tablets-cv-in-adults-with-partial-onset-focal-seizures-at-the-aan-2022-annual-meeting-301514199.html
https://www.prnewswire.com/news-releases/sk-life-science-to-present-latest-xcopri-cenobamate-tablets-cv-data-at-the-american-academy-of-neurology-2022-annual-meeting-301509479.html
https://www.pharmatimes.com/news/nice_recommends_cenobamate_for_treatment_of_adult_epilepsy_patients_in_uk_1383466
https://www.prnewswire.com/news-releases/epilepsia-publishes-two-post-hoc-analyses-from-long-term-study-of-xcopri-cenobamate-tablets-cv-301397427.html
http://www.pharmafile.com/news/580283/epilepsy-drug-receives-mhra-marketing-authorisation
https://www.fiercepharma.com/marketing/two-ads-for-two-audiences-sk-life-s-dual-campaign-target-docs-and-patients-for-anti
http://www.pharmatimes.com/news/ec_approval_for_ontozry_1366390
http://www.pharmafile.com/news/574339/ec-grants-marketing-authorisation-angelini-pharma-s-epilepsy-treatment
https://www.prnewswire.com/news-releases/ontozry-cenobamate-receives-european-commission-approval-for-the-treatment-of-drug-resistant-focal-onset-seizures-in-adults-301259077.html
https://www.prnewswire.com/news-releases/cenobamate-receives-positive-chmp-opinion-for-adjunctive-treatment-of-focal-onset-partial-onset-seizures-301218227.html
https://www.biospace.com/article/releases/ontozry-cenobamate-receives-positive-chmp-opinion-for-the-adjunctive-treatment-of-uncontrolled-focal-onset-seizures-in-adults-/
https://www.fiercepharma.com/marketing/sk-life-science-debuts-first-product-a-virtual-experience-at-a-virtual-aes
https://www.globenewswire.com/news-release/2020/08/11/2076072/0/en/Cenobamate-Designated-Promising-Innovative-Medicine-PIM-by-the-UK-s-MHRA-for-Treatment-of-Drug-Resistant-Focal-Onset-Seizures-in-Adults.html
https://endpts.com/sk-biopharmaceuticals-emerges-from-pandemic-delays-with-pitch-for-822m-ipo/
https://www.biospectrumasia.com/news/25/16094/sk-biopharmaceuticals-receives-new-drug-development-awards.html
https://www.globenewswire.com/news-release/2020/05/21/2036784/0/en/Results-of-a-Randomised-Study-Showing-that-Adjunctive-Cenobamate-Significantly-Improved-Seizure-control-in-Adults-with-Uncontrolled-Focal-Seizures-Published-in-Neurology-1.html
http://www.pharmafile.com/news/574339/ec-grants-marketing-authorisation-angelini-pharma-s-epilepsy-treatment
http://www.pharmatimes.com/news/ema_accepts_arvelles_cenobamate_maa_1330204
https://www.prnewswire.com/news-releases/european-medicines-agency-accepts-arvelle-therapeutics-marketing-authorization-application-for-cenobamate-for-the-adjunctive-treatment-of-focal-onset-seizures-in-adults-301030417.html
https://www.empr.com/home/news/epilepsy-therapy-xcopri-designated-schedule-v-controlled-substance/
https://www.prnewswire.com/news-releases/fda-approves-new-treatment-for-adults-with-partial-onset-seizures-300963454.html
https://www.prnewswire.com/news-releases/fda-approves-xcopri-cenobamate-tablets-an-anti-epileptic-drug-aed-from-sk-biopharmaceuticals-co-ltd-and-us-subsidiary-sk-life-science-inc-300963478.html
Market Place
Share 
